Literature DB >> 6091571

Abnormal monocyte cytotoxicity and cyclic-AMP levels in systemic sclerosis.

T Herlin, J Eggert, K Kragballe, H Zachariae.   

Abstract

Monocyte antibody-dependent cell-mediated cytotoxicity (ADCC) was compared to intrinsic cyclic-adenosine-monophosphate (cAMP) levels in 14 patients with systemic sclerosis. Depressed monocyte cytotoxicity was observed. Elevated cAMP levels (2-5 times) in resting monocytes were found in 5 patients; the rest had normal cAMP values. Monocyte ADCC was inversely correlated to cellular cAMP content (r = -0.6659, P less than 0.02). Scleroderma patients with high basal cAMP levels showed impaired responses to beta-adrenergic stimulation but not to prostaglandin E (PGE1) and histamine. Patients with normal basal cAMP levels showed no defect in beta-adrenergic responses. No close correlation between monocyte abnormality and clinical state was found.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091571     DOI: 10.1007/bf00404617

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  22 in total

1.  Antibody-dependent lymphocyte mediated cytotoxicity mechanism and modulation by cyclic nucleotides.

Authors:  M R Garovoy; T B Strom; M Kaliner; C B Carpenter
Journal:  Cell Immunol       Date:  1975-12       Impact factor: 4.868

2.  The role of calcium and cyclic adenosine 3',5'-monophosphate in the regulation of glycogen metabolism in phagocytozing human polymorphonuclear leukocytes.

Authors:  T Herlin; C S Petersen; V Esmann
Journal:  Biochim Biophys Acta       Date:  1978-08-03

3.  Modulation of polymorphonuclear leukocyte-mediated antibody-dependent cellular cytotoxicity.

Authors:  R P Gale; J Zighelboim
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

4.  Neutrophil chemotaxis in systemic lupus erythematosus.

Authors:  R A Clark; H R Kimball; J L Decker
Journal:  Ann Rheum Dis       Date:  1974-03       Impact factor: 19.103

5.  Antinuclear antibodies: their significance in scleroderma.

Authors:  R E Jordon; D Deheer; A Schroeter; R K Winkelmann
Journal:  Mayo Clin Proc       Date:  1971-02       Impact factor: 7.616

6.  Reduction of phagocytosis and lysosomal enzyme release from human leukocytes by serum from patients with systemic lupus erythematosus.

Authors:  R B Zurier
Journal:  Arthritis Rheum       Date:  1976 Jan-Feb

7.  Neutrophil function in systemic lupus erythematosus and other collagen diseases.

Authors:  H Al-Hadithy; D A Isenberg; I E Addison; A H Goldstone; M L Snaith
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

8.  Prostacyclin increases cyclic-nucleotide responsiveness of lymphocytes from patients with systemic sclerosis.

Authors:  J D Kirby; D R Lima; P M Dowd; S Kilfeather; P Turner
Journal:  Lancet       Date:  1980-08-30       Impact factor: 79.321

9.  Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).

Authors:  P M Dowd; M F Martin; E D Cooke; S A Bowcock; R Jones; P A Dieppe; J D Kirby
Journal:  Br J Dermatol       Date:  1982-01       Impact factor: 9.302

10.  Impaired monocyte cyclic AMP responses and monocyte cytotoxicity in atopic dermatitis.

Authors:  T Herlin; K Kragballe
Journal:  Allergy       Date:  1980-12       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.